AMSTERDAM – A growing epidemic of antimicrobial-resistance (AMR) has cast a heavy load on the laps of antibiotic drug developers. They face challenges in identifying new targets and the particular organism causing the infection, in finding patients to treat at the right time, and in understanding variability in response. If that isn't enough, the money is scarce, costing the same in development as many other drugs, but lacking the blockbuster potential.